– USA, NV –  Spectrum Pharmaceuticals Inc., (NASDAQ:SPPI) a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, today announced the appointment of Jeffrey Vacirca, MD, FACP to its Board of Directors.

Dr. Vacirca is a practicing oncologist and the current president of the Community Oncology Alliance, an advocacy group focused on supporting community oncology clinics. Additionally, Dr. Vacirca is the medical director of the nation’s largest community oncology group purchasing organization, International Oncology Network and the CEO and managing partner at North Shore Hematology Oncology Associates. He also serves as the vice chairman at Odonate Therapeutics (NASDAQ: ODT), an oncology company focused on treating metastatic breast cancer. Furthermore, he has joined the Board of Directors for One Oncology, an oncologist-led company providing oncologists with innovative tools to help keep cancer care in the hands of the providers.

“As a prominent leader within community oncology, Dr. Vacirca has a reputation and clear understanding of how to successfully develop and commercialize oncology pharmaceuticals,” said Joe Turgeon, President and Chief Executive Officer of Spectrum Pharmaceuticals. “His expertise working across multiple stakeholders including patient advocacy groups, clinical investigators, group purchasing organizations, and government agencies is invaluable and precisely what is needed as Spectrum advances its two late-stage pipeline products, poziotinib and ROLONTIS.”

“Joining the Spectrum Board provides me the rare opportunity to fulfill a passion for patient care while working with a company developing life changing therapies,” said Dr. Vacirca. “Poziotinib has the potential to change the treatment paradigm for a subset of cancer patients that have had no adequate treatment options. Additionally, Spectrum has developed a novel G-CSF, which is the first new drug in over fifteen years for use in chemotherapy induced neutropenia.”

With Dr. Vacirca’s appointment, the Spectrum Board increases to nine directors, each of whom are nominated annually by the nominating and corporate governance committee.

About the Spectrum’s Late-Stage Pipeline

Spectrum Pharmaceuticals has two promising late-stage therapies including poziotinib, an investigational therapy targeting the exon 20 insertion mutation. There are currently no FDA approved targeted therapies for the exon 20 mutation. Poziotinib is currently being studied in a pivotal, multicenter Phase 2 trial for non-small cell lung cancer for patients with the exon 20 mutation. Recent data from an MD Anderson Phase 2 study of poziotinib demonstrated strong efficacy in metastatic, heavily pretreated EGFR and HER2 exon 20 mutant NSCLC patients. The second late-stage pipeline product, ROLONTIS (eflapegrastim), is a novel G-CSF therapy being investigated for use in chemotherapy induced neutropenia. Spectrum Pharmaceuticals plans to file a BLA submission with the FDA for ROLONTIS by the end of 2018.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in hematology and oncology. Spectrum currently markets six hematology/oncology drugs and has an advanced stage pipeline that has the potential to transform the company. Spectrum’s strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies.

For more information : http://www.sppirx.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Comments are closed.